Evidence map›Paper›PMID 42365147›Full record

ArticleNeurology and therapy2026

Extended Preoperative Immunotherapy Duration Reduces the Risk of Myasthenia Gravis Exacerbation for Patients with Thymoma: A Multicenter Retrospective Cohort Study.

Jialin Chen, Hongxi Chen, Xianglin Chu, Jie Song, Nana Zhang, Huahua Zhong, Zhangyu Zou, Hui Wu, Liewen Pang, Chongbo Zhao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jialin Chen *Huashan Rare Disease Center & Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Hongxi Chen *Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Xianglin ChuDepartment of Thoracic Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Jie SongHuashan Rare Disease Center & Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Nana ZhangDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Huahua ZhongHuashan Rare Disease Center & Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Zhangyu ZouDepartment of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Hui WuDepartment of Neurology, Jing'an District Centre Hospital of Shanghai, Shanghai, China.
Liewen PangDepartment of Thoracic Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Chongbo ZhaoHuashan Rare Disease Center & Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Hongyu ZhouDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, China. zhouhy@scu.edu.cn.
Zhitao GuDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 728001425@shsmu.edu.cn.
Sushan LuoHuashan Rare Disease Center & Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China. luosushan@fudan.edu.cn.ORCID http://orcid.org/0000-0002-9033-7568

Funding

National Clinical Collaboration Project for Major and Difficult Diseases with Integrated Traditional Chinese and Western Medicine o. GTCM Integration Letter [2023] No. 250National Natural Science Foundation of China 82471426National Natural Science Foundation of China 82571592
6 · The paper itself

Abstract

introductionPatients with thymoma-associated myasthenia gravis (TAMG) frequently have a higher risk for clinical deterioration. Previous studies primarily focused on postoperative myasthenic crisis (MC), leaving intermediate and long-term MG outcomes after thymectomy largely unexplored. This study aimed to identify predictors of postoperative acute exacerbation within 1 year after thymectomy and explore the potential benefits of preoperative immunotherapies.

methodsThis multicenter retrospective study enrolled 347 patients with TAMG from 1756 individuals between February 2008 and October 2024. The primary endpoint was defined as the occurrence of acute exacerbation within 1 year postoperatively. Statistical evaluation employed logistic regression, Cox proportional hazards models, receiver operating characteristic analysis, and Kaplan-Meier curves.

resultsOf the study cohort, 96 patients (27.7%) had postoperative acute exacerbation of MG within 1 year. Multivariate Cox regression analysis identified that preoperative Myasthenia Gravis Foundation of America (MGFA) III-V was an independent risk factor for postoperative acute exacerbation (hazard ratio, HR 3.913, P < 0.001); preoperative immunotherapy duration > 14 days was associated with a protective effect (HR 0.419, P < 0.001). Multivariate logistic regression analysis identified preoperative MGFA III-V (odds ratio, OR 0.392, P < 0.05), reduced rate of R0 resection (OR 0.440, P < 0.05), and postoperative acute exacerbation (OR 0.245, P < 0.001) as independent risk predictors for achieving minimal symptom expression (MSE) at 1 year postoperatively.

conclusionA preoperative immunotherapy duration exceeding 14 days is crucial for improving postoperative outcomes for TAMG.

Indexed as

Minimal symptom expressionPostoperative acute exacerbationPreoperative immunotherapyThymoma-associated myasthenia gravis

Identifiers

PMID42365147
PMCPMC13396320

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.